Immunocore (NASDAQ:IMCR) Announces Quarterly Earnings Results, Misses Estimates By $0.01 EPS

Immunocore (NASDAQ:IMCR) released its quarterly earnings results on Thursday. The company reported ($0.02) EPS for the quarter, missing the consensus estimate of ($0.01) by ($0.01), FiscalAI reports. Immunocore had a negative return on equity of 4.63% and a negative net margin of 4.20%.The company had revenue of $115.93 million for the quarter, compared to analyst estimates of $148.52 million.

Here are the key takeaways from Immunocore’s conference call:

• Positive Sentiment: KIMMTRAK first-half net revenue rose 16% year over year to $223 million, including $116 million in Q2, supported by continued U.S. community demand and penetration above 70% in major markets.
• Positive Sentiment: Five-year data showed KIMMTRAK doubled the likelihood of survival at five years versus investigator’s choice in HLA-A2-positive metastatic uveal melanoma, with overall survival of 16% versus 8%.
• Positive Sentiment: Enrollment in the pivotal TEBE-AM trial for previously treated advanced cutaneous melanoma is nearly complete, with headline overall-survival data potentially available by year-end 2026; ATOM and PRISM-MEL-301 also continue to advance.
• Neutral Sentiment: Immunocore expects first-patient dosing of its type 1 diabetes candidate in the coming weeks, plans to submit a CTA for a second autoimmune candidate by year-end, and expects updated HIV data in the first half of 2027.
• Negative Sentiment: Q2 U.S. sales benefited from approximately $6 million of distributor inventory stocking, creating a headwind for Q3, while the company expects roughly $120 million in sales-related rebate payments during the second half of 2026.

Immunocore Stock Down 1.4%

Shares of IMCR stock traded down $0.50 during mid-day trading on Friday, reaching $34.00. 492,085 shares of the company were exchanged, compared to its average volume of 545,841. The company has a debt-to-equity ratio of 1.00, a quick ratio of 4.15 and a current ratio of 4.18. The business’s 50 day simple moving average is $31.64 and its 200 day simple moving average is $31.35. The company has a market capitalization of $1.73 billion, a P/E ratio of -91.89 and a beta of 0.74. Immunocore has a fifty-two week low of $27.56 and a fifty-two week high of $40.71.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in the stock. Orion Porfolio Solutions LLC grew its holdings in Immunocore by 4.5% in the 2nd quarter. Orion Porfolio Solutions LLC now owns 23,965 shares of the company’s stock worth $752,000 after buying an additional 1,031 shares in the last quarter. Arax Advisory Partners raised its position in shares of Immunocore by 302.9% during the 4th quarter. Arax Advisory Partners now owns 1,386 shares of the company’s stock worth $48,000 after buying an additional 1,042 shares in the last quarter. Osaic Holdings Inc. lifted its stake in shares of Immunocore by 117.4% in the 2nd quarter. Osaic Holdings Inc. now owns 3,148 shares of the company’s stock worth $97,000 after acquiring an additional 1,700 shares during the period. Legal & General Group Plc lifted its stake in shares of Immunocore by 2.0% in the 3rd quarter. Legal & General Group Plc now owns 125,756 shares of the company’s stock worth $4,562,000 after acquiring an additional 2,517 shares during the period. Finally, Federation des caisses Desjardins du Quebec boosted its holdings in shares of Immunocore by 162.1% in the fourth quarter. Federation des caisses Desjardins du Quebec now owns 5,478 shares of the company’s stock valued at $190,000 after acquiring an additional 3,388 shares in the last quarter. 84.50% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

A number of research analysts have recently commented on IMCR shares. Wall Street Zen cut shares of Immunocore from a “buy” rating to a “hold” rating in a research report on Tuesday, July 28th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Immunocore in a report on Friday, July 17th. Morgan Stanley set a $43.00 price target on shares of Immunocore in a research note on Friday. HC Wainwright reiterated a “buy” rating and issued a $100.00 price objective on shares of Immunocore in a report on Monday, April 20th. Finally, Mizuho upped their price objective on shares of Immunocore from $34.00 to $35.00 and gave the company a “neutral” rating in a research report on Monday, August 3rd. One research analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating, four have assigned a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, Immunocore presently has a consensus rating of “Moderate Buy” and an average price target of $57.29.

Trending Headlines about Immunocore

Here are the key news stories impacting Immunocore this week:

• Positive Sentiment: Kimmtrak revenue increased 18.3% year over year, supported by higher sales in the United States and international markets. The drug remains Immunocore’s sole commercial product and the primary driver of revenue growth. Immunocore’s Q2 Earnings Miss Estimates, Kimmtrak Aids Y/Y Revenues
• Positive Sentiment: Zacks Research upgraded Immunocore from “hold” to “strong-buy.” Separately, the average Wall Street price target implies substantial potential upside, although price-target accuracy is uncertain. Immunocore analyst upgrade Wall Street Analysts See a 77.91% Upside in Immunocore
• Neutral Sentiment: Management’s second-quarter earnings presentation and conference call highlighted Kimmtrak growth and the company’s development pipeline. Investors will likely focus on the pace of commercial expansion and progress toward additional pipeline opportunities. Immunocore 2026 Q2 Results Presentation
• Negative Sentiment: Immunocore reported a second-quarter loss of $0.02 per share, wider than the $0.01 expected loss. Revenue was approximately $115.9 million; while sales grew year over year, this figure was below the cited analyst consensus of $148.4 million. The company also remained unprofitable, increasing concern about the timing of sustainable earnings. Immunocore Q2 Earnings Report

About Immunocore

Immunocore plc is a clinical?stage biotechnology company focused on the development of novel immunotherapies that harness the body’s own T?cell response to treat cancer and infectious diseases. The company’s proprietary ImmTAC (immune mobilising monoclonal T?cell receptors against cancer) platform utilizes engineered, soluble T?cell receptor (TCR) molecules designed to recognise intracellular peptide–HLA complexes. By redirecting and activating T cells against disease?associated targets, Immunocore aims to address malignancies and persistent viral infections with high unmet medical need.

The company’s most advanced candidate, tebentafusp, is a bispecific ImmTAC molecule that targets gp100, a melanoma?associated antigen, and has received regulatory approval for the treatment of metastatic uveal melanoma.